Agaricus Blazei for Anti-Inflammatory

Research suggests that Agaricus blazei Murill demonstrates consistent anti-inflammatory properties across a range of preclinical studies, with laboratory and animal research showing that its bioactive compounds — particularly polysaccharides such as beta-glucans, as well as phenolics and other constituents — can reduce pro-inflammatory cytokines like TNF-α, IL-1β, IL-6, and markers such as NF-κB, COX-2, and myeloperoxidase, with proposed mechanisms including modulation of immune signaling pathways such as JAK-STAT and Akt. Studies indicate these effects have been observed across diverse experimental models, including animal models of osteoporosis, neuroinflammation, malaria, and UVB-induced skin damage, as well as cell-based assays involving mast cells and keratinocytes, lending breadth if not clinical depth to the overall picture. The body of evidence is composed almost entirely of in vitro and animal studies, along with several narrative and systematic reviews that consistently characterize the preclinical findings as promising; direct human clinical trial data specifically addressing anti-inflammatory outcomes remains sparse, and reviewers across multiple publications have noted that preparations are often unstandardized, mechanisms remain incompletely understood, and well-designed randomized controlled trials in humans are still needed before any firm conclusions about therapeutic efficacy can be drawn.